• Annovis Bio priced a $21 million public offering, including 19,000,000 common shares at $1 each with an accompanying warrant.
• Pre-funded warrants cover 2,000,000 shares at $0.9999 each with an accompanying warrant, in lieu of common shares.
• Accompanying warrants cover 21,000,000 shares, are immediately exercisable at $1 per share and expire five years from issuance.
• Pre-funded warrants carry a $0.0001 exercise price per share, are immediately exercisable and remain exercisable until exercised in full.
• Closing expected November 6, 2026; proceeds fund buntanetap clinical studies, working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050805PRIMZONEFULLFEED9871182) on November 05, 2026, and is solely responsible for the information contained therein.